Yasushi Isobe

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Motoko Yamaguchi, Yok‐Lam Kwong, Won Seog Kim et al. · Journal of Clinical Oncology · 2011 · 602 citations

Pharmacy, Oncology, Pharmacotherapy +13

Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211

Motoko Yamaguchi, Kensei Tobinai, Masahiko Oguchi et al. · Journal of Clinical Oncology · 2009 · 338 citations

Medicine, Oncology, Radiation Oncology +14

Defective Epstein–Barr virus in chronic active infection and haematological malignancy

Yusuke Okuno, Takayuki Murata, Yoshitaka Sato et al. · Nature Microbiology · 2019 · 241 citations

Life Sciences, Hematology, Microbiology +15

Prospective measurement of Epstein-Barr virus–DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type

Ritsuro Suzuki, Motoko Yamaguchi, Koji Izutsu et al. · Blood · 2011 · 193 citations · Full text

Medicine, Immunology, Oncology +10

Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type

Yoshinori Ito, Hiroshi Kimura, Yoshinobu Maeda et al. · Clinical Cancer Research · 2012 · 98 citations

Medicine, Immunology, Oncology +13